Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, Declèves X, Csajka C, Alexandre J, Cadranel J, Fabre E, Wislez M, Goldwasser F, Blanchet B.
Rodier T, et al. Among authors: cardoso e.
Pharmaceutics. 2022 Sep 1;14(9):1844. doi: 10.3390/pharmaceutics14091844.
Pharmaceutics. 2022.
PMID: 36145591
Free PMC article.